Phosphodiesterase 4 Inhibitor Use in Pediatric Patients With Atopic Dermatitis: A Meta-Analysis of Randomized Controlled Trials.

Advances in skin & wound care·April 1, 2026·PMID: 41860296

What's New

Topical PDE4 inhibitors were associated with significantly higher treatment success rates compared to vehicle control in pediatric patients with mild-to-moderate atopic dermatitis.

Detailed Summary

A meta-analysis of 5 RCTs (n=1,877) found that topical PDE4 inhibitors were associated with higher Investigator Global Assessment response rates (OR 3.56; 95% CI, 2.09-6.04) and greater treatment success at weeks 2 and 4 compared to vehicle control, with no significant differences in adverse events.

Study Population

pediatric patients with mild-to-moderate atopic dermatitis (n=1,877 across 5 RCTs)

This research is for informational purposes only — discuss with your doctor before making any changes to your care.

Discuss This with a Pediatric Dermatologist

Rivvet may earn a referral fee if you book through this link.

Share:
Share on X

Discussion

Loading comments...

Comments are public. Be respectful and remember: this is not medical advice. Do not share personal health information.

0/1000

Want more research like this? Sign up free